IN8bio Stock Price, News & Analysis (NASDAQ:INAB) $0.83 +0.05 (+6.87%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$0.77▼$0.8850-Day Range$0.69▼$1.2352-Week Range$0.65▼$3.95Volume308,402 shsAverage Volume1.13 million shsMarket Capitalization$26.64 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media IN8bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,220.8% Upside$11.00 Price TargetShort InterestHealthy0.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.85Based on 4 Articles This WeekInsider TradingAcquiring Shares$2,375 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.93) to ($0.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.59 out of 5 starsMedical Sector99th out of 949 stocksBiological Products, Except Diagnostic Industry13th out of 157 stocks 3.5 Analyst's Opinion Consensus RatingIN8bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, IN8bio has a forecasted upside of 1,220.8% from its current price of $0.83.Amount of Analyst CoverageIN8bio has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.13% of the float of IN8bio has been sold short.Short Interest Ratio / Days to CoverIN8bio has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IN8bio has recently decreased by 50.98%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIN8bio does not currently pay a dividend.Dividend GrowthIN8bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INAB. Previous Next 3.2 News and Social Media Coverage News SentimentIN8bio has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for IN8bio this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for INAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added IN8bio to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IN8bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,375.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders33.00% of the stock of IN8bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.37% of the stock of IN8bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IN8bio are expected to grow in the coming year, from ($0.93) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IN8bio is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IN8bio is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIN8bio has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IN8bio Stock (NASDAQ:INAB)IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Read More INAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INAB Stock News HeadlinesNovember 28, 2023 | finance.yahoo.comHarnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio’s Innovative ApproachNovember 23, 2023 | finance.yahoo.comHere's Why IN8bio, Inc. (INAB) Could be Great Choice for a Bottom FisherNovember 29, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 20, 2023 | finanznachrichten.deIN8bio, Inc: IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed GlioblastomaNovember 20, 2023 | finance.yahoo.comIN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed GlioblastomaNovember 15, 2023 | markets.businessinsider.comPromising Future for IN8bio: Anticipated Data Presentations, Capital Raise, and Innovative DevelopmentsNovember 10, 2023 | finance.yahoo.comIN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual MeetingNovember 9, 2023 | msn.comIN8bio GAAP EPS of -$0.23November 29, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 9, 2023 | finance.yahoo.comIN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 8, 2023 | morningstar.comIN8bio Inc Ordinary Shares INABNovember 6, 2023 | finance.yahoo.comHow IN8bio Is Working To Reach Its Goal Of “Cancer Zero” – Making Cancer A Thing of The PastNovember 2, 2023 | tmcnet.comIN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual MeetingNovember 1, 2023 | finance.yahoo.comIN8bio to Participate at the 2023 Truist Securities BioPharma SymposiumOctober 13, 2023 | markets.businessinsider.comBuy Recommendation for IN8bio: Anticipated Funding, Clinical Validation, and Key Developments Drive Positive OutlookSeptember 29, 2023 | markets.businessinsider.comAnalyst Maintains Buy Rating for IN8bio Based on Positive SITC Release and Promising R&D DevelopmentsSeptember 29, 2023 | finance.yahoo.comIN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual MeetingSeptember 26, 2023 | finance.yahoo.comIN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York CitySeptember 20, 2023 | seekingalpha.comIN8bio director Graff Jeremy acquires 2,500 company sharesSeptember 20, 2023 | finance.yahoo.comIN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 19, 2023 | finance.yahoo.comIN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global PatentsSeptember 6, 2023 | finance.yahoo.comIN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 15, 2023 | finance.yahoo.comIN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual ConferenceAugust 13, 2023 | finance.yahoo.comCompanies Like IN8bio (NASDAQ:INAB) Could Be Quite RiskyAugust 11, 2023 | markets.businessinsider.comIN8bio (INAB) Gets a Buy from H.C. WainwrightAugust 11, 2023 | finanznachrichten.deIN8bio, Inc: IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 11, 2023 | markets.businessinsider.comMizuho Securities Sticks to Their Buy Rating for IN8bio (INAB)See More Headlines Receive INAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INAB CUSIPN/A CIK1740279 Webwww.in8bio.com Phone646-600-6438FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$14.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,311.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-152.81% Return on Assets-106.33% Debt Debt-to-Equity Ratio0.04 Current Ratio3.53 Quick Ratio3.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book1.39Miscellaneous Outstanding Shares31,990,000Free Float21,434,000Market Cap$24.93 million OptionableNot Optionable Beta-0.22 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Tai-Wei Ho (Age 46)Co-Founder, President, CEO & Director Comp: $837kDr. Kate Rochlin Ph.D. (Age 42)Chief Operating Officer Comp: $565.4kDr. Trishna Goswami M.D. (Age 45)Chief Medical Officer Comp: $638.51kDr. Lawrence S. Lamb Ph.D. (Age 69)Executive VP, Co-Founder & Chief Scientific Officer Comp: $482.47kMr. Patrick McCall CPA (Age 40)CFO & Secretary Comp: $519.35kKey CompetitorsPluriNASDAQ:PLURCandel TherapeuticsNASDAQ:CADLNanoString TechnologiesNASDAQ:NSTGEvaxion Biotech A/SNASDAQ:EVAXCortexymeNASDAQ:CRTXView All CompetitorsInsiders & InstitutionsRock Creek Group LPBought 75,000 shares on 11/13/2023Ownership: 0.473%Voss Capital LLCBought 53,708 shares on 10/19/2023Ownership: 1.619%Jeremy R GraffBought 2,500 shares on 9/13/2023Total: $2,375.00 ($0.95/share)Patrick MccallBought 1,000 shares on 8/25/2023Total: $1,030.00 ($1.03/share)William Tai-Wei HoBought 23,800 shares on 8/24/2023Total: $24,990.00 ($1.05/share)View All Insider TransactionsView All Institutional Transactions INAB Stock Analysis - Frequently Asked Questions Should I buy or sell IN8bio stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INAB shares. View INAB analyst ratings or view top-rated stocks. What is IN8bio's stock price target for 2024? 2 brokerages have issued 12 month price targets for IN8bio's stock. Their INAB share price targets range from $8.00 to $14.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,220.8% from the stock's current price. View analysts price targets for INAB or view top-rated stocks among Wall Street analysts. How have INAB shares performed in 2023? IN8bio's stock was trading at $2.31 at the beginning of 2023. Since then, INAB stock has decreased by 63.9% and is now trading at $0.8328. View the best growth stocks for 2023 here. Are investors shorting IN8bio? IN8bio saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 27,600 shares, a decrease of 51.0% from the October 31st total of 56,300 shares. Based on an average daily trading volume, of 108,700 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company's stock are sold short. View IN8bio's Short Interest. When is IN8bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our INAB earnings forecast. How were IN8bio's earnings last quarter? IN8bio, Inc. (NASDAQ:INAB) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.11. When did IN8bio IPO? (INAB) raised $44 million in an IPO on Friday, July 30th 2021. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share. B. Riley Securities served as the underwriter for the IPO. Who are IN8bio's major shareholders? IN8bio's stock is owned by many different institutional and retail investors. Top institutional investors include Voss Capital LLC (1.62%) and Rock Creek Group LP (0.47%). Insiders that own company stock include Emily Fairbairn, Jeremy R Graff, Kate Rochlin, Lawrence Lamb, Patrick Mccall, Trishna Goswami and William Tai-Wei Ho. View institutional ownership trends. How do I buy shares of IN8bio? Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:INAB) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.